Eyegate Pharmaceuticals (EYEG) Earns “Buy” Rating from HC Wainwright

Eyegate Pharmaceuticals (NASDAQ:EYEG)‘s stock had its “buy” rating reiterated by equities researchers at HC Wainwright in a report released on Tuesday, MarketBeat reports. They presently have a $3.00 target price on the specialty pharmaceutical company’s stock, down from their prior target price of $5.00. HC Wainwright’s target price would indicate a potential upside of 361.54% from the company’s previous close.

Separately, ValuEngine upgraded Eyegate Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Friday.

Shares of Eyegate Pharmaceuticals (NASDAQ EYEG) traded up $0.05 during trading on Tuesday, reaching $0.65. The company had a trading volume of 691,785 shares, compared to its average volume of 432,523. The company has a market capitalization of $17.72, a price-to-earnings ratio of -0.55 and a beta of 2.91. Eyegate Pharmaceuticals has a 1-year low of $0.49 and a 1-year high of $3.90. The company has a quick ratio of 0.81, a current ratio of 0.81 and a debt-to-equity ratio of 0.01.

Eyegate Pharmaceuticals (NASDAQ:EYEG) last issued its quarterly earnings results on Tuesday, November 14th. The specialty pharmaceutical company reported ($0.24) EPS for the quarter, hitting the Zacks’ consensus estimate of ($0.24). Eyegate Pharmaceuticals had a negative return on equity of 1,494.75% and a negative net margin of 2,480.28%. research analysts anticipate that Eyegate Pharmaceuticals will post -1.01 EPS for the current fiscal year.

An institutional investor recently bought a new position in Eyegate Pharmaceuticals stock. Sabby Management LLC bought a new stake in Eyegate Pharmaceuticals Inc (NASDAQ:EYEG) during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 345,524 shares of the specialty pharmaceutical company’s stock, valued at approximately $473,000. Sabby Management LLC owned 2.01% of Eyegate Pharmaceuticals at the end of the most recent reporting period. 11.94% of the stock is currently owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION WARNING: “Eyegate Pharmaceuticals (EYEG) Earns “Buy” Rating from HC Wainwright” was posted by American Banking News and is the property of of American Banking News. If you are reading this story on another domain, it was illegally stolen and republished in violation of US & international copyright & trademark laws. The legal version of this story can be read at https://www.americanbankingnews.com/2018/02/06/eyegate-pharmaceuticals-eyeg-earns-buy-rating-from-hc-wainwright.html.

About Eyegate Pharmaceuticals

Eyegate Pharmaceuticals, Inc is a clinical-stage specialty pharmaceutical company. The Company is focused on developing and commercializing therapeutics and drug delivery systems for treating diseases of the eye. The Company’s lead product, EGP-437, incorporates a reformulated topically active corticosteroid, dexamethasone phosphate, which is delivered into the ocular tissues through its drug delivery system, the EyeGate II Delivery System.

Receive News & Ratings for Eyegate Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eyegate Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply